RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma Ltd. has announced that its drug Talicia® is now recommended as a first-line treatment for H. pylori infections in the new American College of Gastroenterology guidelines, due to its high eradication rates and minimal antibiotic resistance. Talicia® offers a simplified treatment regimen, potentially improving patient outcomes and addressing antibiotic resistance concerns. The drug is also covered by U.S. patents extending protection until 2034, with additional international patents pending.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
